{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T04:54:11Z","timestamp":1764996851611,"version":"3.30.0"},"reference-count":55,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2495,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,11]]},"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>\n                                 <jats:bold>Hepatitis C virus (HCV) infection is especially problematic in patients with end-stage renal disease (ESRD) who are undergoing hemodialysis. Rates of HCV infection are higher among hemodialysis patients than in the general population, and several routes of transmission are thought to stem from the dialysis unit. Management of chronic hepatitis C is also more complicated in hemodialysis patients because of altered pharmacokinetics and a predisposition for drug-related toxicity, particularly ribavirin-induced anemia. Clinical trials of patients with chronic hepatitis C and healthy, functioning kidney grafts are rare because of the inherent dangers of graft rejection. As a result, most studies in patients with ESRD have focused on patients waiting for a kidney transplant. Additionally, because ribavirin is contraindicated in this patient population, many studies have examined monotherapy treatments. According to meta-analyses, conventional interferon alfa treatment yields a sustained virological response (SVR) rate of 37%, whereas studies of pegylated interferon alfa monotherapy have yielded SVR rates between 13% and 75%. Several small studies have also used the monitoring of ribavirin plasma concentrations or hemoglobin levels to facilitate the use of combination therapy. In light of the results from these clinical trials, we herein review treatment guidelines and recommend strategies to help optimize the treatment of patients with ESRD.<\/jats:bold>\n                                 <jats:bold>\n                                    Conclusion:\n                                 <\/jats:bold>\n                                 <jats:bold>There remains a lack of clarity surrounding the most effective treatment options for patients with chronic hepatitis C and ESRD. Treatment can be effective with many patients attaining SVR; however, unfavorable tolerability with interferon alfa\u2013based therapy remains a concern and thus close supportive care should be aggressively pursued to help maintain adherence. (Hepatology 2008;48:1690\u20131699.)<\/jats:bold>\n                              <\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.22545","type":"journal-article","created":{"date-parts":[[2008,7,28]],"date-time":"2008-07-28T15:13:16Z","timestamp":1217257996000},"page":"1690-1699","update-policy":"http:\/\/dx.doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":54,"title":["Treatment of chronic hepatitis C in hemodialysis patients"],"prefix":"10.1097","volume":"48","author":[{"given":"Marina","family":"Berenguer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-38-20241201","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1053\/jhep.2002.34613","article-title":"Hepatitis C infection and the patient with endstage renal disease.","volume":"36","author":"Fabrizi","year":"2002","journal-title":"HEPATOLOGY"},{"key":"R2-38-20241201","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1055\/s-2004-832931","article-title":"Hepatitis C infection associated with renal disease and chronic renal failure.","volume":"24","author":"Poordad","year":"2004","journal-title":"Semin Liver Dis"},{"issue":"Suppl 109","key":"R3-38-20241201","first-page":"S46","article-title":"3: preventing HCV transmission in hemodialysis units.","volume":"73","year":"2008","journal-title":"Kidney Int"},{"key":"R4-38-20241201","doi-asserted-by":"crossref","first-page":"149","DOI":"10.5414\/CNP69149","article-title":"Hepatitis C virusrelated kidney disease: an overview.","volume":"69","author":"Kamar","year":"2008","journal-title":"Clin Nephrol"},{"key":"R5-38-20241201","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1089\/jir.1982.2.301","article-title":"The kidney is the main site of interferon degradation.","volume":"2","author":"Bino","year":"1982","journal-title":"J Interferon Res"},{"key":"R6-38-20241201","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000045125","article-title":"Interferon therapy for chronic hepatitis C in hemodialysis patients: increased serum levels of interferon.","volume":"80","author":"Uchihara","year":"1998","journal-title":"Nephron"},{"key":"R7-38-20241201","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1177\/009127002237996","article-title":"Singledose pharmacokinetics and safety of pegylated interferonalpha2b in patients with chronic renal dysfunction.","volume":"42","author":"Gupta","year":"2002","journal-title":"J Clin Pharmacol"},{"key":"R11-38-20241201","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1478-3231.2005.01225.x","article-title":"Efficacy and tolerance of interferon in the treatment of chronic hepatitis C in endstage renal disease patients on hemodialysis.","volume":"26","author":"Rocha","year":"2006","journal-title":"Liver Int"},{"key":"R12-38-20241201","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/ndt\/16.5.1017","article-title":"The tolerance and efficacy of interferon in haemodialysis patients with HCV infection: a multicentre, prospective study.","volume":"16","author":"Degos","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"R13-38-20241201","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1093\/ndt\/12.7.1414","article-title":"Interferon treatment for hepatitis C virus infection in patients on haemodialysis.","volume":"12","author":"Chan","year":"1997","journal-title":"Nephrol Dial Transplant"},{"key":"R14-38-20241201","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/j.transproceed.2005.02.054","article-title":"Treatment of hepatitis C virus with interferon in hemodialysis patients awaiting kidney transplant.","volume":"37","author":"Rivera","year":"2005","journal-title":"Transplant Proc"},{"key":"R15-38-20241201","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1179\/joc.2005.17.6.651","article-title":"Interferon alpha monotherapy for chronic hepatitis C viral infection in thalassemics and hemodialysis patients.","volume":"17","author":"Artan","year":"2005","journal-title":"J Chemother"},{"key":"R16-38-20241201","first-page":"220","article-title":"Interferon therapy in hemodialysis patients with chronic hepatitis C virus infection induces a high rate of longterm sustained virological and biochemical response.","volume":"55","author":"Espinosa","year":"2001","journal-title":"Clin Nephrol"},{"key":"R17-38-20241201","doi-asserted-by":"crossref","first-page":"c133","DOI":"10.1159\/000085442","article-title":"Interferon therapy in hemodialysis patients with chronic hepatitis C: study of tolerance, efficacy and posttransplantation course.","volume":"100","author":"Mahmoud","year":"2005","journal-title":"Nephron Clin Pract"},{"key":"R18-38-20241201","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1081\/JDI-200031725","article-title":"A sixyear followup after interferonalpha monotherapy for chronic hepatitis C infection in hemodialysis patients.","volume":"26","author":"Ozdemir","year":"2004","journal-title":"Ren Fail"},{"key":"R19-38-20241201","doi-asserted-by":"crossref","first-page":"c8","DOI":"10.1159\/000090505","article-title":"Efficacy of interferon in the treatment of chronic hepatitis C in dialysis patients: two therapeutic protocols compared.","volume":"103","author":"Grgurevic","year":"2006","journal-title":"Nephron Clin Pract"},{"key":"R20-38-20241201","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1046\/j.1365-2036.2003.01780.x","article-title":"Metaanalysis: interferon for the treatment of chronic hepatitis C in dialysis patients.","volume":"18","author":"Fabrizi","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"R21-38-20241201","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1111\/j.1572-0241.2003.07526.x","article-title":"Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety.","volume":"98","author":"Russo","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"R22-38-20241201","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM199811193392101","article-title":"Interferon alfa2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C.","volume":"339","author":"McHutchison","year":"1998","journal-title":"N Engl J Med"},{"key":"R23-38-20241201","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/S0140-6736(98)07124-4","article-title":"Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus.","volume":"352","author":"Poynard","year":"1998","journal-title":"Lancet"},{"key":"R24-38-20241201","first-page":"794","article-title":"Analysis of safety and efficacy of pegylatedinterferon alpha2a in hepatitis C virus positive hemodialysis patients: results from a large, multicenter audit.","volume":"19","author":"Covic","year":"2006","journal-title":"J Nephrol"},{"key":"R25-38-20241201","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/ndt\/gfi231","article-title":"Randomized trial of pegylated interferon 2b monotherapy in haemodialysis patients with chronic hepatitis C.","volume":"21","author":"Russo","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"R26-38-20241201","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1440-1797.2006.00662.x","article-title":"Pilot study of pegylated interferonalpha 2a in dialysis patients with chronic hepatitis C virus infection.","volume":"12","author":"Chan","year":"2007","journal-title":"Nephrology (Carlton)"},{"key":"R27-38-20241201","doi-asserted-by":"crossref","first-page":"4191","DOI":"10.3748\/wjg.v12.i26.4191","article-title":"Pegylatedinterferon alpha 2a treatment for chronic hepatitis C in patients on chronic haemodialysis.","volume":"12","author":"Sporea","year":"2006","journal-title":"World J Gastroenterol"},{"key":"R28-38-20241201","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1365-2036.2004.01954.x","article-title":"Pegylated interferonalpha 2b monotherapy for haemodialysis patients with chronic hepatitis C.","volume":"20","author":"Annicchiarico","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"R29-38-20241201","first-page":"16","article-title":"Monotherapy with peginterferon alpha2b 12 kDa for chronic hepatitis C infection in patients undergoing haemodialysis.","volume":"28","author":"Amarapurkar","year":"2007","journal-title":"Trop Gastroenterol"},{"key":"R30-38-20241201","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/j.transproceed.2007.07.013","article-title":"Preliminary results of treatment with pegylated interferon alpha 2A for chronic hepatitis C virus in kidney transplant candidates on hemodialysis.","volume":"39","author":"CasanovasTaltavull","year":"2007","journal-title":"Transplant Proc"},{"issue":"Suppl","key":"R31-38-20241201","first-page":"363A","article-title":"Treatment of hemodialysis (HD) patients with chronic hepatitis C (CHC) using an escalating dose regimen of pegylated interferon (PEGIFN) alfa2b. Abstract.","volume":"46","author":"Tan","year":"2007","journal-title":"HEPATOLOGY"},{"key":"R32-38-20241201","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1440-1746.2005.04008.x","article-title":"Efficacy and tolerability of pegylatedinterferon alpha2a in hemodialysis patients with chronic hepatitis C.","volume":"21","author":"Kokoglu","year":"2006","journal-title":"J Gastroenterol Hepatol"},{"key":"R33-38-20241201","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1046\/j.1365-2893.2001.00300.x","article-title":"Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection-a pilot study.","volume":"8","author":"Bruchfeld","year":"2001","journal-title":"J Viral Hepat"},{"key":"R34-38-20241201","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/j.1365-2893.2005.00680.x","article-title":"Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients.","volume":"13","author":"Bruchfeld","year":"2006","journal-title":"J Viral Hepat"},{"key":"R35-38-20241201","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/j.transproceed.2004.07.025","article-title":"Alphainterferon with ribavirin in the treatment of hemodialysis patients with hepatitis C.","volume":"36","author":"Mousa","year":"2004","journal-title":"Transplant Proc"},{"key":"R37-38-20241201","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/ndt\/16.1.193","article-title":"Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: results of a pilot study.","volume":"16","author":"Tan","year":"2001","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl","key":"R38-38-20241201","first-page":"703A","article-title":"Safety and tolerability of pegylated interferon with or without low dose ribavirin for treatment of hepatitis C in hemodialysis. Abstract.","volume":"42","author":"Luxon","year":"2005","journal-title":"HEPATOLOGY"},{"key":"R40-38-20241201","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/ndt\/gfm724","article-title":"Pegylated interferon alfa2a (40 kD) and ribavirin in haemodialysis patients with chronic hepatitis C.","volume":"23","author":"van Leusen","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"R41-38-20241201","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1177\/039139880803100404","article-title":"Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and lowdose ribavirin.","volume":"31","author":"Carriero","year":"2008","journal-title":"Int J Artif Organs"},{"key":"R42-38-20241201","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1046\/j.1365-2125.1998.00836.x","article-title":"Ribavirin and interferon alfa2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions.","volume":"46","author":"Khakoo","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"R43-38-20241201","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jhep.2006.12.016","article-title":"The treatment of chronic hepatitis C with peginterferon alfa2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant.","volume":"46","author":"Rendina","year":"2007","journal-title":"J Hepatol"},{"key":"R44-38-20241201","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/00007890-200101270-00018","article-title":"Kidney transplantation for endstage renal failure in liver transplant recipients with hepatitis C viral infection.","volume":"71","author":"Molmenti","year":"2001","journal-title":"Transplantation"},{"key":"R45-38-20241201","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1097\/00007890-199705150-00016","article-title":"Renal disease in hepatitis Cpositive liver transplant recipients.","volume":"63","author":"Kendrick","year":"1997","journal-title":"Transplantation"},{"key":"R46-38-20241201","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1053\/jlts.2002.36241","article-title":"Ribavirin dose modification based on renal function is necessary to reduce hemolysis in liver transplant patients with hepatitis C virus infection.","volume":"8","author":"Jain","year":"2002","journal-title":"Liver Transpl"},{"key":"R47-38-20241201","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jhep.2008.05.002","article-title":"Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin.","volume":"49","author":"Berenguer","year":"2008","journal-title":"J Hepatol"},{"key":"R48-38-20241201","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1093\/ndt\/gfm678","article-title":"Alphainterferon therapy for chronic hepatitis C may induce acute allograft rejection in kidney transplant patients with failed allografts.","volume":"23","author":"Weclawiack","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"R49-38-20241201","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/01.mcg.0000225569.04773.8b","article-title":"Treatment with pegylated interferon and ribavirin for hepatitis C virusassociated severe cryoglobulinemia in a liverkidney transplant recipient.","volume":"41","author":"Montalbano","year":"2007","journal-title":"J Clin Gastroenterol"},{"key":"R50-38-20241201","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1016\/S0041-1345(99)00603-X","article-title":"Effect of interferonalpha treatment in hemodialysis patients and renal transplant recipients with chronic hepatitis C.","volume":"31","author":"Tokumoto","year":"1999","journal-title":"Transplant Proc"},{"key":"R51-38-20241201","first-page":"1891","article-title":"Severe relapse of hepatitis C following liver transplantation; successful treatment with a combination of interferonalpha and ribavirin.","volume":"140","author":"Telegdy","year":"1999","journal-title":"Orv Hetil"},{"key":"R52-38-20241201","first-page":"1170","article-title":"Efficacy of interferon for chronic hepatitis C virusrelated hepatitis in kidney transplant candidates on hemodialysis: results after transplantation.","volume":"96","author":"CasanovasTaltavull","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"R53-38-20241201","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1097\/01.TP.0000128911.87538.AA","article-title":"Histopathologic efficacy of ribavirin monotherapy in kidney allograft recipients with chronic hepatitis C.","volume":"78","author":"Fontaine","year":"2004","journal-title":"Transplantation"},{"key":"R54-38-20241201","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000085455","article-title":"Ribavirin treatment in patients with chronic hepatitis C infection who had renal transplantation.","volume":"22","author":"Karaca","year":"2005","journal-title":"Dig Surg"},{"key":"R55-38-20241201","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jcv.2007.02.006","article-title":"Combination therapy with ribavirin and amantadine in renal transplant patients with chronic hepatitis C virus infection is not superior to ribavirin alone.","volume":"39","author":"Calanca","year":"2007","journal-title":"J Clin Virol"},{"key":"R56-38-20241201","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1053\/j.gastro.2005.11.010","article-title":"American Gastroenterological Association technical review on the management of hepatitis C.","volume":"130","author":"Dienstag","year":"2006","journal-title":"Gastroenterology"},{"key":"R57-38-20241201","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/hep.20119","article-title":"Diagnosis, management, and treatment of hepatitis C.","volume":"39","author":"Strader","year":"2004","journal-title":"HEPATOLOGY"},{"issue":"Suppl","key":"R58-38-20241201","first-page":"368A","article-title":"Predictors of sustained virological response to interferonbased treatment in hemodialysis patients with chronic hepatitis C virus infectiona patient level metaanalysis. Abstract.","volume":"46","author":"Gordon","year":"2007","journal-title":"HEPATOLOGY"},{"issue":"Suppl 109","key":"R59-38-20241201","first-page":"S10","article-title":"1: detection and evaluation of HCV in CKD.","volume":"73","year":"2008","journal-title":"Kidney Int"},{"issue":"Suppl 109","key":"R60-38-20241201","first-page":"S20","article-title":"2: treatment of HCV infection in patients with CKD.","volume":"73","year":"2008","journal-title":"Kidney Int"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.22545","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-200811000-00038","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T13:41:47Z","timestamp":1733060507000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-200811000-00038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11]]},"references-count":55,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.22545","relation":{},"ISSN":["0270-9139"],"issn-type":[{"type":"print","value":"0270-9139"}],"subject":[],"published":{"date-parts":[[2008,11]]}}}